| Code | CSB-RA011649MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to daclizumab, targeting IL2RA (Interleukin-2 Receptor Alpha, also known as CD25). IL2RA is the alpha subunit of the high-affinity interleukin-2 receptor complex, expressed primarily on activated T cells, regulatory T cells, and certain B cells. This receptor plays a critical role in T cell proliferation, differentiation, and immune response regulation. Dysregulation of IL2RA expression is implicated in various autoimmune disorders, transplant rejection, and hematological malignancies, making it an important target for immunological research.
Daclizumab is a humanized IgG1 monoclonal antibody that specifically binds to IL2RA, blocking interleukin-2 mediated activation of lymphocytes. Originally approved for preventing organ transplant rejection and later investigated for multiple sclerosis treatment, daclizumab has been extensively studied in immunology research. This biosimilar antibody provides researchers with a valuable tool for investigating IL2RA-mediated signaling pathways, T cell activation mechanisms, immune tolerance, and potential therapeutic interventions in autoimmune diseases and transplantation biology.
There are currently no reviews for this product.